



Personalized Medicine in Cancer Therapy: Mechanism, Approaches and Techniques

Guest Editors:

Dr. Michele Zanoni

Istituto Romagnolo per lo Studio
dei Tumori "Dino Amadori"-IRST
S.r.l., 47014 Meldola, Italy

Dr. Michela Cortesi

Istituto Romagnolo per lo Studio
dei Tumori "Dino Amadori" - IRST
S.r.l., 47014 Meldola, Italy

Deadline for manuscript
submissions:

closed (30 June 2022)

Message from the Guest Editors

Personalized medicine differs from standard treatment approaches due to the identification of factors (e.g., molecular features, phenotypes, environment, biomarkers) making individual patients eligible for a specific treatment. The tumor microenvironment (TME) is attracting growing attention in cancer research. This highly complex network composed of non-tumor cells, extracellular matrix (ECM) proteins, and secreted factors modulates and is modulated by malignant cells. The dynamic landscape of the TME impacts on treatment outcome, leading to therapy resistance, and contributes to tumor heterogeneity, which represents a critical factor driving tumor progression and dissemination. This Special Issue will host review, opinion, short communication, and research articles focusing on personalized medicine-exploring strategies to model and target the TME. We particularly welcome articles integrating preclinical models (e.g., 3D models, organoids), omics (e.g., metabolomics, proteomics, genomics), and bioinformatics analyses. Special attention will be given to cross-disciplinary approaches involving clinicians, biologists, chemists, physicists, etc.

Dr. Michele Zanoni

Dr. Michela Cortesi





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA

2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPi](https://twitter.com/JPM_MDPi)